S/N 09/730,374

PATENT

IN THE UNIXED STATES PATENT AND TRADEMARK OFFICE

Applicant:

John A. Lust et al.

Examiner: Unknown

Serial No.:

09/730,374

Group Art Unit: Unknown

Filed:

December 5, 2000

Docket: 150.188US2

Title:

USE OF GENETICALLY ENGINEERED ANTIBODIES TO CD38 TO TREAT

MULTIPLE MYELOMA

COMMUNICATION UNDER 37 C.F.R. § 1.821

Commissioner for Patents Washington, D.C. 20231

Sir:

A SEQUENCE LISTING, to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 through 1.825, is submitted herewith.

In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith. It is respectfully submitted that the contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same.

Respectfully submitted,

JOHN A. LUST ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date May 7, 2001

Janet E. Embretson

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 7 day of May, 2001.

____ III Schrank

Signature



SEQUENCE LISTING

<110> Lust, John A. Donovan, Kathleen A.

<120> USE OF GENETICALLY ENGINEERED ANTIBODIES TO CD38 TO TREAT MULTIPLE MYELOMA

<130> 150.188US2 <140> 09/730,374 <141> 2000-12-05 <150> PCT/US99/12512 <151> 1999-06-04 <150> 60/088,277 <151> 1998-08-05 <160> 4 <170> FastSEO for Windows Version 4.0

<210> 1 <211> 750 <212> DNA <213> Artificial Sequence

<220>

<223> A nucleotide sequence encoding a single chain variable region fragment (scFv)

<400> 1 60 qqcccaqccq qccatqqcca aqqtccaqct gcaggagtca ggacctagcc tagtgcagcc 120 ctcacagege etgtecataa eetgeacagt etetggttte teattaatta gttatggtgt acactgggtt cgccagtctc caggaaaggg tctggagtgg ctgggagtga tatggagagg 180 tggaagcaca gactacaatg cagctttcat gtccagactg agcatcacca aggacaactc 240 caaqaqccaa gttttcttta aaatgaacag tctgcaagct gatgacactg ccatatactt 300 ctgtgccaaa accttgatta cgacgggcta tgctatggac tactggggcc aagggaccac 360 420 qqtcaccqtc tcctcaggtg gaggcggttc aggcggaggt ggctctggcg gtggcggatc ggacatcgag ctcactcagt ctccatcctc cttttctgta tctctaggag acagagtcac 480 cattacttgc aaggcaagtg aggacatata taatcggtta gcctggtatc agcagaaacc 540 aggaaatgct cctaggctct taatatctgg tgcaaccagt ttggaaactg gggttccttc 600 aagattcagt ggcagtggat ctggaaagga ttacactctc agcattacca gtcttcagac 660 720 tgaagatgtt gctacttatt actgtcaaca gtattggagt actcctacgt tcggtggagg 750 gaccaagctg gaaatcaaac gggcggccgc

<210> 2 <211> 241 <212> PRT <213> Artificial Sequence <220>

<223> A polypeptide encoded by an open reading frame of SEQ ID NO:1

Gly Pro Ala Gly His Gly Gln Gly Pro Ala Ala Gly Val Arg Thr Pro Ser Ala Ala Leu Thr Ala Pro Val His Asn Leu His Ser Leu Trp Phe Leu Ile Asn Leu Trp Cys Thr Leu Gly Ser Pro Val Ser Arg Lys Gly 40 Ser Gly Val Ala Gly Ser Asp Met Glu Arg Trp Lys His Arg Leu Gln 55 Cys Ser Phe His Val Gln Thr Glu His His Gln Gly Gln Leu Gln Glu 75 Pro Ser Phe Leu Asn Glu Gln Ser Ala Ser His Cys His Ile Leu Leu Cys Gln Asn Leu Asp Tyr Asp Gly Leu Cys Tyr Gly Leu Leu Gly Pro Arg Asp His Gly His Arg Leu Leu Arg Trp Arg Arg Phe Arg Arg Arg 120 Trp Leu Trp Arg Trp Arg Ile Gly His Arg Ala His Ser Val Ser Ile 135 Leu Leu Phe Cys Ile Ser Arg Arg Gln Ser His His Tyr Leu Gln Gly 155 150 Lys Gly His Ile Ser Val Ser Leu Val Ser Ala Glu Thr Arg Lys Cys 170 165 Ser Ala Leu Asn Ile Trp Cys Asn Gln Phe Gly Asn Trp Gly Ser Phe 185 Lys Ile Gln Trp Gln Trp Ile Trp Lys Gly Leu His Ser Gln His Tyr 200 Gln Ser Ser Asp Arg Cys Cys Tyr Leu Leu Leu Ser Thr Val Leu Glu 215 220 Tyr Ser Tyr Val Arg Trp Arg Asp Gln Ala Gly Asn Gln Thr Gly Gly 235 Arg

<210> 3 <211> 249 <212> PRT <213> Artificial Sequence

<223> A polypeptide encoded by an open reading frame of SEQ ID NO:1

<400> 3 Ala Gln Pro Ala Met Ala Lys Val Gln Leu Gln Glu Ser Gly Pro Ser 10 Leu Val Gln Pro Ser Gln Arg Leu Ser Ile Thr Cys Thr Val Ser Gly 25 Phe Ser Leu Ile Ser Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly 40 Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Arg Gly Gly Ser Thr Asp 55 Tyr Asn Ala Ala Phe Met Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asp Asp Thr 90 Ala Ile Tyr Phe Cys Ala Lys Thr Leu Ile Thr Thr Gly Tyr Ala Met

105 100 Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly 120 Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu 135 Thr Gln Ser Pro Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr 150 155 Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr 170 165 Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr 185 Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 200 Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala 215 Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Thr Phe Gly Gly 235 Thr Lys Leu Glu Ile Lys Arg Ala Ala 245

<210> 4

<211> 239

<212> PRT

<213> Artificial Sequence

<220>

<223> A polypeptide encoded by an open reading frame of SEQ ID NO:1

Pro Ser Arg Pro Trp Pro Arg Ser Ser Cys Arg Ser Gln Asp Leu Ala 10 Cys Ser Pro His Ser Ala Cys Pro Pro Ala Gln Ser Leu Val Ser His 25 Leu Val Met Val Tyr Thr Gly Phe Ala Ser Leu Gln Glu Arg Val Trp 40 45 Ser Gly Trp Glu Tyr Gly Glu Val Glu Ala Gln Thr Thr Met Gln Leu Ser Cys Pro Asp Ala Ser Pro Arg Thr Thr Pro Arg Ala Lys Phe Ser Leu Lys Thr Val Cys Lys Leu Met Thr Leu Pro Tyr Thr Ser Val Pro 90 Lys Pro Leu Arg Arg Ala Met Leu Trp Thr Thr Gly Ala Lys Gly Pro 105 Arg Ser Pro Ser Pro Gln Val Glu Ala Val Gln Ala Glu Val Ala Leu 120 Ala Val Ala Asp Arg Thr Ser Ser Ser Leu Ser Leu His Pro Pro Phe 135 140 Leu Tyr Leu Glu Thr Glu Ser Pro Leu Leu Ala Arg Gln Val Arg Thr 150 155 Tyr Ile Ile Gly Pro Gly Ile Ser Arg Asn Gln Glu Met Leu Leu Gly 170 165 Ser Tyr Leu Val Gln Pro Val Trp Lys Leu Gly Phe Leu Gln Asp Ser 185 Val Ala Val Asp Leu Glu Arg Ile Thr Leu Ser Ala Leu Pro Val Phe 200 Arg Leu Lys Met Leu Leu Leu Ile Thr Val Asn Ser Ile Gly Val Leu 210 215 220

Leu Arg Ser Val Glu Gly Pro Ser Trp Lys Ser Asn Gly Arg Pro
225 230 235

To to